- Catalogue N°
- 855.870.000 - 200µg / 200µl
855.870.005 - 500µg / 500µl
- Target species
- Recognises both natural and recombinant human Galectin-9 protein
- Myeloma X63/AG.8653 x Balb/c node cells
- Recombinant human galectin-9
- 200µg or 500µg (Discovery Size also available please enquire)
- Mouse IgG1 Kappa light chain
- Phosphate-buffered saline. Sterile-filtered through 0.22 µm. Carrier and preservative free
- Stable at +2-8°C for 12 months. For longer storage freeze aliquots.
Galectins is a family of non-classically secreted, β-galactoside-binding proteins that has recently received considerable attention.
Galectin-9 is a unique member of this family with a 39kDa tandem-repeat type galectin with two carbohydrate-recognition domains. It was first identified as an eosinophil chemoattractant and activation factor and first cloned from tumor tissues of Hodgkin’s disease. Subsequent studies revealed that galectin-9, similar to other galectins, modulates a variety of biological functions including cell aggregation and adhesion, as well as apoptosis of tumor cells. Galectin-9 has recently been shown to have an anti-proliferative effect on cancer cells. Recent studies have uncovered additional mechanisms by which T cell immunoglobulin mucin-3 (TIM-3), a receptor for galectin-9, negatively regulates T cell responses by promoting CD8+ T cell exhaustion and inducing expansion of myeloid-derived suppressor cells. These mechanisms are involved in tumor growth and escape from immunity. In many solid cancers, the loss of galectin-9 expression is closely associated with metastatic progression, and treatment with recombinant galectin-9 prevents metastatic spread in various preclinical cancer models.
Version 5 - 06.19
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.